1.
Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression
by Luo, Ming
Cancer letters, 2013, Vol.333 (2), p.213-221
2.
Influence of Body Mass Index on Operability, Morbidity and Disease Outcome following Radical Cystectomy
by Maurer, Tobias
Urologia internationalis, 2009, Vol.82 (4), p.432-439
3.
Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications
by Sanguedolce, Francesca
Oncology, 2021, Vol.99 (6), p.345-358
4.
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC
by Kamat, Ashish M
Future oncology (London, England), 2020, Vol.16 (10), p.507-516
5.
Progress in the development of tissue-based biomarkers for urothelial cancer
by Bhanvadia, Raj R.
Expert review of anticancer therapy, 2022, Vol.22 (6), p.605-619
6.
Comparison of Thulium Laser Resection of Bladder Tumors and Conventional Transurethral Resection of Bladder Tumors for Non-Muscle-Invasive Bladder Cancer
by Liu, Zheng
Urologia internationalis, 2022, Vol.106 (2), p.116-121
7.
Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer
by Iliev, Robert
Tumor biology, 2016, Vol.37 (10), p.13385-13390
8.
An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies
by Witlox, Willem J. A
European journal of nutrition, 2019, Vol.59 (1), p.287-296
9.
Beyond BCG: the approaching era of personalised bladder-sparing therapies for non-muscle-invasive urothelial cancers
by Young, Francis P
Future oncology (London, England), 2018, Vol.15 (4), p.409-420
10.
Incidental Bladder Cancer Found on Cystoscopy during Prostate Biopsy: Prevalence, Pathological Findings, and Oncological Outcome
by Tohi, Yoichiro
Urologia internationalis, 2022, Vol.106 (8), p.791-797
11.
Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries
by Suarez-Ibarrola, Rodrigo
Urologia internationalis, 2020, Vol.104 (5-6), p.410-416
12.
13.
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer
by Katz, Heather
Medical oncology (Northwood, London, England), 2017, Vol.34 (10), p.170-170
14.
High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer
by Ayari, Cherifa, PhD
Human pathology, 2013, Vol.44 (8), p.1630-1637
15.
Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non–muscle invasive bladder cancer
by Fahmy, Mona
Human pathology, 2013, Vol.44 (9), p.1766-1772
16.
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer
by Pinto-Leite, Rosário
Tumor biology, 2014, Vol.35 (5), p.4599-4617
17.
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study
by Serretta, Vincenzo
Urologia internationalis, 2020, Vol.104 (5-6), p.396-401
18.
Comment on: Relationship between the expression of PD-1/PD-L1 and 18.sup.F-FDG uptake in bladder cancer
by Girard, Antoine
European journal of nuclear medicine and molecular imaging, 2019, Vol.46 (6), p.1212
19.
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer
by Koie, Takuya
Medical oncology (Northwood, London, England), 2014, Vol.31 (5), p.949
20.
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials
by Heijl, C
Annals of the rheumatic diseases, 2011, Vol.70 (8), p.1415-1421
